Actively Recruiting
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Led by Innovent Biologics Technology Limited (Shanghai R&D Center) · Updated on 2026-01-08
800
Participants Needed
1
Research Sites
38 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
CONDITIONS
Official Title
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form before participating
- Male or female aged 50 years or older at consent
- Active choroidal neovascularization (CNV) under or involving the macular fovea due to nAMD
- Best corrected visual acuity of the study eye between 19 and 78 ETDRS letters at baseline
You will not qualify if you...
- Ocular or systemic diseases in the study eye that may interfere with treatment response or study results
- Uncontrollable glaucoma in the study eye
- Active intraocular or periocular infection or inflammation in either eye
- Severe visual function disorders in the non-study eye
- Anti-VEGF treatment in the study eye within 90 days before baseline
- Anti-complement treatment in the study eye within 90 days before baseline
- Prior IBI302 treatment in the study eye before baseline
- Uncontrollable hypertension
- Glycated hemoglobin (HbA1c) above 10.0% within 28 days before screening
- Other exclusion criteria per protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai general hospital
Shanghai, Shanghai Municipality, China, P. R. China 200080
Actively Recruiting
Research Team
Y
Yating Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here